Day: March 20, 2023

CalciMedica Announces Closing of Merger with Graybug Vision and Concurrent Private Placement

CalciMedica Announces Closing of Merger with Graybug Vision and Concurrent Private Placement

– CalciMedica common stock to commence trading on Nasdaq Global Market on March 21, 2023 under ticker symbol “CALC”– Cash and cash equivalents of approximately $34 million as of merger close expected to support operations into the second half of 2024– Phase 2b results in acute pancreatitis for lead product candidate Auxora™ expected in Q4 2023– CalciMedica to host Research and Development Event on April 27, 2023 LA JOLLA, Calif., March 20, 2023 (GLOBE NEWSWIRE) — CalciMedica Inc. (CalciMedica) (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing therapies for life-threatening inflammatory diseases with high unmet need, today announced the closing of its previously announced merger with Graybug Vision, Inc. CalciMedica’s stock will commence trading on March 21, 2023 on the...

Continue reading

Bluejay Diagnostics Reports 2022 Financial Results

Bluejay Diagnostics Reports 2022 Financial Results

ACTON, Mass., March 20, 2023 (GLOBE NEWSWIRE) — Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a medical diagnostics company developing rapid tests using whole blood on its Symphony platform to improve patient outcomes in critical care settings, today reported its financial results for the year ended December 31, 2022. “Significant developmental strides were made during 2022, with our IL-6 clinical study data affirming the potential of Bluejay’s Symphony System to be a rapid and precise testing platform for near-patient management in critical care settings,” said Neil Dey, CEO of Bluejay Diagnostics. “Recent positive feedback from the FDA indicated an expansion of our clinical study would be necessary to support our planned de novo submission, extending our anticipated submission timeline to the first half...

Continue reading

Eterna Therapeutics Reports Financial Results for Fourth Quarter and Full Year 2022 and Recent Business Highlights

Eterna Therapeutics Reports Financial Results for Fourth Quarter and Full Year 2022 and Recent Business Highlights

– Executed income generating license agreement with Lineage Cell Therapeutics to develop gene-edited induced pluripotent stem cell (iPSC)-derived therapies for multiple neurology indications – Entered into a sublease agreement with Bristol Myers Squibb to occupy 45,000 sq. ft. of lab and office space at Cambridge Crossing development in Cambridge, Massachusetts – Appointed Matt Angel, Ph.D. as Chief Executive Officer and President CAMBRIDGE, Mass., March 20, 2023 (GLOBE NEWSWIRE) — Eterna Therapeutics Inc. (Nasdaq: ERNA) (“Eterna” or the “Company”), a life science company committed to realizing the potential of mRNA cell engineering to provide patients with transformational new medicines, today announced financial results for the quarter and year ended December 31, 2022 and provided a business update. “2022 was a transformational...

Continue reading

Canterbury Park Holding Corporation Reports 2022 Fourth Quarter Results

Canterbury Park Holding Corporation Reports 2022 Fourth Quarter Results

SHAKOPEE, Minn., March 20, 2023 (GLOBE NEWSWIRE) — Canterbury Park Holding Corporation (“Canterbury” or the “Company”) (NASDAQ: CPHC), today reported financial results for the fourth quarter and full year ended December 31, 2022. ($ in thousands, except per share data and percentages)     Three Months Ended December 31,   Twelve Months Ended December 31,     2022   2021   Change(3)   2022   2021   Change   Net revenues(2) $13,119   $13,955   -6.0%   $66,824   $60,400   10.6%                             Net income(2) $1,063   $6,620   -83.9%   $7,513   $11,798   -36.3%                             Adjusted EBITDA(3) $2,687   $3,360   -20.0%   $15,141   $13,471   12.4%                             Basic EPS $0.22   $1.38   -84.1%   $1.55   $2.47   -37.2%   Diluted EPS $0.22   $1.37   -83.9%   $1.54   $2.44   -36.9% (1) Financial...

Continue reading

Exagen Inc. Reports Fourth Quarter and Full Year 2022 Results

Exagen Inc. Reports Fourth Quarter and Full Year 2022 Results

Record AVISE® CTD Volume in 2022 SAN DIEGO, March 20, 2023 (GLOBE NEWSWIRE) — Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported financial results for the fourth quarter and full year ended December 31, 2022. Recent Highlights: Record 135,210 flagship AVISE® CTD tests, for the full year 2022, including 33,819 tests for the fourth quarter of 2022. Since the launch of AVISE® CTD in 2012, we have now delivered approximately 750,000 of these tests. Total revenue of $45.6 million for the year ended December 31, 2022, and total revenue of $12.8 million for the fourth quarter of 2022. John Aballi, President and CEO, joined the Company in the fourth quarter of 2022 and implemented a new strategy focused on reducing cash burn and driving ASP and GM improvement to ultimately reach profitability...

Continue reading

CERBERUS CYBER SENTINEL ANNOUNCES PRELIMINARY ESTIMATED FINANCIAL INFORMATION

CERBERUS CYBER SENTINEL ANNOUNCES PRELIMINARY ESTIMATED FINANCIAL INFORMATION

Receives $5.0 million from private convertible note offering Scottsdale, Ariz., March 20, 2023 (GLOBE NEWSWIRE) — via InvestorWire — Cerberus Cyber Sentinel Corporation (“Cerberus Sentinel” or the “Company”) (NASDAQ: CISO), an industry leader as a managed cybersecurity and compliance provider, based in Scottsdale, Ariz., today announced certain preliminary estimated financial information as of and for the quarter and fiscal year ended December 31, 2022. The preliminary estimated financial information has been prepared by, and is the responsibility of, the Company’s management. Semple, Marchal & Cooper, LLP, the Company’s independent registered public accounting firm, has not audited, reviewed, compiled or performed any procedures with respect to the preliminary estimated financial information provided below. The Company’s...

Continue reading

CROSSJECT - 2022 Annual Results

CROSSJECT – 2022 Annual Results

Press release 2022 annual resultsA year of major developmentsSubstantial increase in operating income Dijon, 20 March 2023, 8.00 p.m. CROSSJECT (ISIN: FR0011716265; Ticker: ALCJ), a specialty pharma company that is developing and will soon be marketing a portfolio of drugs for use in emergency situations (epilepsy, allergic shock, overdose, asthma attack, adrenal insufficiency, etc.), presents its annual results for 2022. “In 2022, Crossject experienced a truly unprecedented year in its history. The growth embedded in contracts signed to date offers unique visibility and marks the turning point we have been waiting for. Optimising our resources to support Crossject’s ramp-up is now our priority, along the lines of the non-dilutive financing we have implemented. Thanks to the efforts of all our teams and the support of our shareholders,...

Continue reading

IBEX Reports Results for the Second Quarter and the Six Months Ended January 31, 2023

IBEX Reports Results for the Second Quarter and the Six Months Ended January 31, 2023

MONTREAL, March 20, 2023 (GLOBE NEWSWIRE) — IBEX Technologies Inc. (“IBEX” or the “Company”) (TSX Venture: IBT) today reported its financial results for the second quarter and the six months ended January 31, 2023. “Our results for this reporting period, while lower than year ago, were above expectations since many of our customers were drawing down prior year’s inventories faster than we forecasted. While revenues were down 6% in the period, they were up 31% from the same period in fiscal 2021. We now expect that revenues, while lower than the exceptional 2022 fiscal year, to be significantly higher than fiscal year 2021,” said Paul Baehr, IBEX President & CEO. “The engine for this growth is the underlying increasing demand and market penetration of our major customers in the high-growth, hemostasis-rapid-testing market segment”. Note:...

Continue reading

Metaverse in FnB Market is Expected to Surpass USD 10.45 Billion by 2030 at a CAGR of 32.46% from 2022 to 2030; Immersive Dining Experience, Virtual Ordering, and Delivery Make Metaverse in FnB an Attractive Option

Metaverse in FnB Market is Expected to Surpass USD 10.45 Billion by 2030 at a CAGR of 32.46% from 2022 to 2030; Immersive Dining Experience, Virtual Ordering, and Delivery Make Metaverse in FnB an Attractive Option

The SkyQuest research on the Metaverse in the FnB market is an excellent guide for anyone looking to learn about this rapidly expanding market. Also, the report’s writing is concise, making it understandable to readers, from business insiders to laypeople. Last but not least, it provides readers with a thorough understanding of the principal and secondary market drivers and provides them with a comprehensive view of the present market condition and future estimates. Westford USA, March 20, 2023 (GLOBE NEWSWIRE) — The Metaverse in the FnB market is expected to experience significant growth in North America and Asia Pacific regions. Several factors drive this growth, including Immersive dining experience, virtual ordering and delivery, socializing and entertainment, brand building, and marketing. In addition, utilizing the...

Continue reading

Pennant Acquires Senior Living Operations in Wisconsin

Pennant Acquires Senior Living Operations in Wisconsin

EAGLE, Idaho, March 20, 2023 (GLOBE NEWSWIRE) — The Pennant Group, Inc. (NASDAQ: PNTG), the parent company of the Pennant group of affiliated home health, hospice, home care and senior living companies, today announced that it has completed the acquisition of operations of Robins Landing at New Berlin, a 44-bed memory care and assisted living facility located in New Berlin, Wisconsin, and Robins Landing at Brookfield, a 52-bed memory care and assisted living facility located in Brookfield, Wisconsin. The acquisition was effective March 16, 2023 and will be subject to a long-term, triple-net lease. “We are very excited to expand our senior living offerings in the State of Wisconsin,” said Brent Guerisoli, Chief Executive Officer of Pennant. “This acquisition complements our existing operations in the area, including home health,...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Cookie Notice

We use cookies to improve your experience on our website

Information we collect about your use of Goldea Capital website

Goldea Capital website collects personal data about visitors to its website.

When someone visits our websites, we use a third party service, Google Analytics, to collect standard internet log information (such as IP address and type of browser they’re using) and details of visitor behavior patterns. We do this to allow us to keep track of the number of visitors to the various parts of the sites and understand how our website is used. We do not make any attempt to find out the identities or nature of those visiting our websites. We won’t share your information with any other organizations for marketing, market research or commercial purposes and we don’t pass on your details to other websites.

Use of cookies
Cookies are small text files that are placed on your computer or other device by websites that you visit. They are widely used to make websites work, or work more efficiently, as well as to provide information to the owners of the site.